Form 4: Acrivon CAO Withholds Shares for RSU Tax

Acrivon Therapeutics’ CAO Katharine Peterson had 99 shares withheld at $2.24 on RSU vesting, retaining 4,122 shares directly.

Summary

• On 11/14/2025, Chief Accounting Officer Katharine Peterson reported a tax-withholding transaction (Code F) related to RSU vesting.
• 99 shares of Acrivon Therapeutics common stock were withheld by the issuer at $2.24 per share to satisfy mandatory tax withholding.
• Following the transaction, Peterson directly owns 4,122 shares.
• No open-market purchase or sale occurred; the shares were withheld by the issuer for taxes.
• The Form 4 was signed by Adam D. Levy, Attorney-in-Fact, on 11/18/2025.

Sentiment

Score: 5

Explanation: Routine administrative insider transaction for tax withholding; neutral impact.

Positives

• Transaction was solely for mandatory tax withholding on RSU vesting (Code F), not a discretionary open-market sale.
• Post-transaction direct ownership remains at 4,122 shares, indicating continued alignment with shareholders.

Negatives

• Insider direct holdings decreased by 99 shares due to tax withholding.

Future Outlook

No forward-looking statements or guidance provided.

Management Comments

• Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

Industry Context

This is a routine insider tax-withholding event tied to RSU vesting, a common practice across U.S.-listed biopharma and broader public companies, with no direct implications for operations or strategy.

Comparison to Industry Standards

• Consistent with standard U.S. public company practice to net-settle RSUs for taxes (Form 4 Code F).
• No open-market sale occurred; this mirrors common approaches among biotech peers where issuers withhold shares to cover taxes on vesting.

Stakeholder Impact

• Minor reduction in insider’s direct holdings (down 99 shares) with 4,122 shares remaining directly owned.
• No market liquidity impact from this event since no open-market trade took place.

Key Dates

Keywords

Acrivon Therapeutics, ACRV, Form 4, insider transaction, restricted stock units, RSU vesting, tax withholding, beneficial ownership, Katharine Peterson, Chief Accounting Officer